药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

未开盘 07-11 16:08:03

30.000

+0.000

0.00%

最高30.450	最低29.050	成交量20.95万
今开30.000	昨收30.000	日振幅4.67%
总市值119.07亿	流通市值90.50亿	总股本3.97亿
成交额619.72万	换手率0.07%	流通股本3.02亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":30,"timestamp":1752221283030,"preClose":30,"halted":0,"volume":209500,"delay":0,"floatShares":301666673,"shares":396897633,"eps":-0.7873636854094874,"marketStatus":"未开盘","change":0,"latestTime":"07-11 16:08:03","open":30,"high":30.45,"low":29.05,"amount":6197150,"amplitude":0.046667,"askPrice":30,"askSize":3000,"bidPrice":29.85,"bidSize":3000,"shortable":0,"etf":0,"ttmEps":-0.7873636854094874,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752456600000},"marketStatusCode":0,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":30,"openAndCloseTimeList":[[1752197400000,1752206400000],[1752210000000,1752220800000]],"volumeRatio":0.43896408673493925,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"2550589677","title":"药捷安康-B(02617)股东将股票存入华泰香港 存仓市值14.76亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2550589677","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550589677?lang=zh_cn&edition=full","pubTime":"2025-07-11 08:12","pubTimestamp":1752192779,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，7月10日，药捷安康-B(02617)股东将股票存入华泰香港，存仓市值14.76亿港元，占比15.86%。药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼(TT-00420)，已获美国食品药物管理局(FDA)授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司表示，替恩戈替尼目前处于全球三期注册实验的多靶点激酶抑制剂，靶向FGFR/VEGFR、JAK和Aurora激酶发挥抗肿瘤作用，目前正在美国与中国进行的临床试验显示，其在多种实体瘤治疗中具有疗效潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1316535.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2550680177","title":"药捷安康-B07月09日主力净流入11.9万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2550680177","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2550680177?lang=zh_cn&edition=full","pubTime":"2025-07-09 16:15","pubTimestamp":1752048956,"startTime":"0","endTime":"0","summary":"07月09日, 药捷安康-B股价涨1.15%，报收30.85元，成交金额1391.2万元，换手率0.15%，振幅10.16%，量比0.73。药捷安康-B今日主力资金净流入11.9万元，上一交易日主力净流出87.4万元。该股近5个交易日上涨11.17%，主力资金累计净流出108.2万元；近20日主力资金累计净流入641.3万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170532a43ff84b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250709170532a43ff84b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2549121985","title":"药捷安康-B07月08日主力净流出87.4万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2549121985","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2549121985?lang=zh_cn&edition=full","pubTime":"2025-07-08 16:15","pubTimestamp":1751962536,"startTime":"0","endTime":"0","summary":"07月08日, 药捷安康-B股价跌6.15%，报收30.50元，成交金额1118.0万元，换手率0.12%，振幅6.46%，量比0.45。药捷安康-B今日主力资金净流出87.4万元，上一交易日主力净流出0万元。该股近5个交易日上涨1.16%，主力资金累计净流出199.5万元；近20日主力资金累计净流入629.5万元，其中净流入天数为5日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165413a69cc758&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250708165413a69cc758&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"gpt_icon":0},{"id":"2548151360","title":"2025年港股IPO半年报——专题一：千亿募资破局 A to H 新消费 创新药点燃市场","url":"https://stock-news.laohu8.com/highlight/detail?id=2548151360","media":"新浪证券","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548151360?lang=zh_cn&edition=full","pubTime":"2025-07-04 18:26","pubTimestamp":1751624760,"startTime":"0","endTime":"0","summary":"2025年上半年，共7家A股公司完成港股IPO，合计募资超770亿港元，占IPO总额的72%，直接推升港股IPO募资额复苏。展望2025年下半年，将有数家A股公司登陆港交所，预计募资规模也将比肩上半年A to H募资额水平，进一步巩固大盘股主导地位。工业材料等板块IPO颓势 募资认购收益全面遇冷在A to H、消费、医疗医药等新经济赛道的狂欢图景中，工业、材料、信息技术、金融板块尽显颓势。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704182723a72eaafe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250704182723a72eaafe&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06978","600276","02619","BK1574","BK1161","02565","HSCEI","02617","603288","HSTECH"],"gpt_icon":1},{"id":"2548546503","title":"61岁医药大佬吴永谦，收获一个IPO！市值突破110亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2548546503","media":"Ofweek维科网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548546503?lang=zh_cn&edition=full","pubTime":"2025-07-04 14:07","pubTimestamp":1751609239,"startTime":"0","endTime":"0","summary":"6月23日，创新药企业药捷安康在港上市，上市首日，其股价大涨超78%。此后数个交易日，药捷安康股价持续上涨，目前其市值已突破100亿港元。截至最新收盘，药捷安康总市值为110亿港元。若以此计算，吴永谦身价已经超过了36亿港元。2024年6月，药捷安康再次冲击港交所IPO，直至本次才上市成功。原文标题 : 61岁医药大佬吴永谦，收获一个IPO！","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070414074197998653&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025070414074197998653&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","BK1515","02617","BK1161"],"gpt_icon":0},{"id":"2548636793","title":"四成半IPO募资超1亿美元，上半年44家香港上市、募资1071亿 | 香港IPO市场2025年","url":"https://stock-news.laohu8.com/highlight/detail?id=2548636793","media":"瑞恩资本Ryanbe...","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548636793?lang=zh_cn&edition=full","pubTime":"2025-07-04 13:22","pubTimestamp":1751606520,"startTime":"0","endTime":"0","summary":"2025年上半年，香港新上市公司共44家，募资1070.61亿，新上市数量较上年同期增14家，募资金额按年增加937亿或 7.01倍。其中的3家已获上市委员会批准除牌。2025年上半年通过IPO上市的42家上市公司一共募资1070.61亿，较2024年同期增加 937亿或701.3%，主要原因是香港IPO市场开始大力回暖、以及越来越多的大型A股公司赴港上市。其中，募资超过1亿美元的IPO共19家，相应募资990.35亿，占全部42家IPO数量的45.2%、全部IPO募资的92.5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/stockzmt/2025-07-04/doc-infehues7724473.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["HEXmain","BK1616","LU0211977185.USD","00325","399300","02617","02589","BK1161","BK1213","BK1587","159982","BK1233"],"gpt_icon":1},{"id":"2548867170","title":"药捷安康-B07月02日遭主力抛售79.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2548867170","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548867170?lang=zh_cn&edition=full","pubTime":"2025-07-02 16:15","pubTimestamp":1751444150,"startTime":"0","endTime":"0","summary":"07月02日, 药捷安康-B股价跌7.96%，报收27.75元，成交金额2135.3万元，换手率0.25%，振幅12.94%，量比0.47。药捷安康-B今日主力资金净流出79.4万元，上一交易日主力净流出281.0万元。该股近5个交易日上涨14.88%，主力资金累计净流入654.5万元；近20日主力资金累计净流入749.6万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702171029a4cad748&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250702171029a4cad748&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"gpt_icon":0},{"id":"2548072497","title":"智通特供 | 恒指半年检：“港股通冲退榜”显示，这22只股票或将纳入港股通","url":"https://stock-news.laohu8.com/highlight/detail?id=2548072497","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2548072497?lang=zh_cn&edition=full","pubTime":"2025-07-01 17:31","pubTimestamp":1751362318,"startTime":"0","endTime":"0","summary":"按照惯例，恒生指数半年检将对上市企业在截至6月30日的12个月内的流动性和市值等指标进行考查，并相应调整指数标的，其中也包括港股通标的。那么，按照当前最新的港股通纳入规则，在下一个港股通检讨日，哪些股票或被纳入港股通呢？根据中信证券测算，2019以来在恒生综指公告日与港股通生效日区间内，预测纳入标的相对恒生综指的平均超额收益达到5.5%。此外，上述这22只股票是在9月份有望纳入港股通，但并不代这22只都要等到9月份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1312603.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HSImain","01333","BK1587","MHImain","BK1171","02617","BK1200","02473","02833","BK1592","HSCEI","06681","BK1549","BK1161","00506","BK4614","HSTECH","02589","BK1189","BK1239","BK1175","513600","HSI","HHImain","MCHmain","YANG","BK1233","BK1616"],"gpt_icon":1},{"id":"2547543410","title":"港股异动 | 药捷安康-B(02617)涨超10%再破顶 CCA药物市场增长较快 公司在细分行业研发领先","url":"https://stock-news.laohu8.com/highlight/detail?id=2547543410","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547543410?lang=zh_cn&edition=full","pubTime":"2025-06-30 14:41","pubTimestamp":1751265711,"startTime":"0","endTime":"0","summary":"消息面上，药捷安康宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获美国食品药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。公司在细分行业研发领先，Tinengotinib是全球首个且唯一进入注册临床阶段用于治疗复发或难治性胆管癌患者的FGFR抑制剂。它也是全球首个可能同时抑制FGFR/JAK通路并针对转移性去势抵抗性前列腺癌具有临床疗效证据的研究药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1311644.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161","CCA"],"gpt_icon":1},{"id":"2547505147","title":"61岁医药大佬吴永谦，收获一个IPO！市值突破110亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2547505147","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547505147?lang=zh_cn&edition=full","pubTime":"2025-06-30 14:32","pubTimestamp":1751265144,"startTime":"0","endTime":"0","summary":"6月23日，创新药企业药捷安康在港上市，上市首日，其股价大涨超78%。此后数个交易日，药捷安康股价持续上涨，目前其市值已突破100亿港元。截至最新收盘，药捷安康总市值为110亿港元。最新数据显示，截至2025年6月23日，吴永谦直接或者间接持有药捷安康32.98%的股权，而药石科技则持有药捷安康5.57%的股权。若以此计算，吴永谦身价已经超过了36亿港元。2024年6月，药捷安康再次冲击港交所IPO，直至本次才上市成功。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143304979439e7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250630143304979439e7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09939","BK1574","02617","BK1161","BK1515"],"gpt_icon":1},{"id":"2547058289","title":"5家创新药企完成新一轮融资，包括药捷安康、华卫恒源等","url":"https://stock-news.laohu8.com/highlight/detail?id=2547058289","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2547058289?lang=zh_cn&edition=full","pubTime":"2025-06-30 11:35","pubTimestamp":1751254544,"startTime":"0","endTime":"0","summary":"根据梳理，6月23日~6月29日，至少有5家致力于创新药研发的新锐公司宣布完成新一轮融资，包括药捷安康、华卫恒源等。此次药捷安康全球发售以每股13.15港元定价，共发行15,281,000股，募集资金金额达2.01亿港元。资料显示，药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506301139199530bfae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202506301139199530bfae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161","BK1574","06978"],"gpt_icon":1},{"id":"2546719632","title":"药捷安康-B06月27日获主力加仓87.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2546719632","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2546719632?lang=zh_cn&edition=full","pubTime":"2025-06-27 16:15","pubTimestamp":1751012122,"startTime":"0","endTime":"0","summary":"06月27日, 药捷安康-B股价涨5.51%，报收27.75元，成交金额3813.2万元，换手率0.47%，振幅11.41%，量比0.00。药捷安康-B今日主力资金净流入87.4万元，连续4日净流入，上一交易日主力净流入179.1万元。该股近5个交易日上涨112.93%，主力资金累计净流入1109.9万元；近20日主力资金累计净流入1109.9万元，其中净流入天数为4日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627172424a4c0db8a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250627172424a4c0db8a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617"],"gpt_icon":1},{"id":"1178074725","title":"药捷安康-B上市一周累涨逾100%！核心产品替恩戈替尼获FDA快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=1178074725","media":"老虎资讯综合","labels":["productRelease","policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1178074725?lang=zh_cn&edition=full","pubTime":"2025-06-27 14:05","pubTimestamp":1751004359,"startTime":"0","endTime":"0","summary":"6月27日，港股次新股$药捷安康-B$午后拉升，上市一周累涨逾100%！药捷安康近日宣布，其自主研发的多靶点激酶抑制剂替恩戈替尼，已获$美国食品$药物管理局授予治疗转移性去势抵抗性前列腺癌的快速通道认证。招股书显示，药捷安康是一家以临床需求为导向、处于注册临床阶段的生物制药公司，专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"药捷安康-B上市一周累涨逾100%！核心产品替恩戈替尼获FDA快速通道认证","news_tag":"productRelease,policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1141140888","title":"药捷安康-B续涨7%，总市值逼近100亿港元；该股昨日上市首日飙涨近79%","url":"https://stock-news.laohu8.com/highlight/detail?id=1141140888","media":"老虎资讯综合","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141140888?lang=zh_cn&edition=full","pubTime":"2025-06-24 09:41","pubTimestamp":1750729312,"startTime":"0","endTime":"0","summary":"6月24日，$药捷安康-B(02617)$续涨7%，总市值逼近100亿港元；该股昨日上市首日飙涨近79%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"2545423968","title":"药捷安康-B(02617.HK)：替恩戈替尼(TT-00420)被授予治疗MCRPC快速通道认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2545423968","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545423968?lang=zh_cn&edition=full","pubTime":"2025-06-24 06:33","pubTimestamp":1750717990,"startTime":"0","endTime":"0","summary":"格隆汇6月24日丨药捷安康-B发布公告，美国食品药物管理局授予替恩戈替尼治疗转移性去势抵抗性前列腺癌患者的快速通道认证。mCRPC是导致前列腺癌患者死亡的主要因素。替恩戈替尼就治疗CCA获FDA授予孤儿药及快速通道认证，于中国获国家药品监督管理局突破性疗法认证，就治疗胆道癌获EMA孤儿药认证。替恩戈替尼是全球首个和唯一一个有潜力同时抑制FGFR/JAK通路，且针对mCRPC有临床疗效证据的研究药物。主要结果于2024年ASCO GU公布。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.jrj.com.cn/2025/06/24063351250120.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LU2552382215.SGD","LU0238689110.USD","LU2764263203.CNY","BK4086","IE00B3CCJ633.GBP","LU2764263039.SGD","LU2764262908.HKD","LU2463526074.USD","BK4588","LU0323239441.USD","LU2211817866.USD","LU0154245673.USD","IE00B2PGVK34.USD","00420","LU2552382132.HKD","LU2133065610.SGD","LU2229751404.USD","IE0004091025.USD","BK4585","IE00BZ1G4Q59.USD","SG9999002224.SGD","02617","LU2089279066.USD","IE00BGHQF417.EUR","LU2552382058.USD","BK1160","BK4504","LU0323240290.USD","BK4533","IE00BKVL7J92.USD","SG9999002232.USD","LU2211814178.USD","LU2720916845.USD","TT","LU0154245756.USD","IE0004086264.USD"],"gpt_icon":1},{"id":"2545412373","title":"中信证券保荐生物科技领先公司药捷安康成功登陆港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2545412373","media":"中信证券发布","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2545412373?lang=zh_cn&edition=full","pubTime":"2025-06-23 20:34","pubTimestamp":1750682096,"startTime":"0","endTime":"0","summary":"2025年6月23日，中信证券作为联席保荐人、联席整体协调人、联席全球协调人、联席账簿管理人及联席牵头经办人，助力药捷安康（南京）科技股份有限公司成功于港交所主板上市，发行规模约2.0亿港币。中信证券全球投资银行管理委员会联席主任程杰出席上市仪式。本项目是中信证券推动服务创新型生物医药行业的又一典型案例。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623204753a718d6f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250623204753a718d6f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1147","06030","BK1521","LU1720050803.USD","BK1516","BK1564","LU1794554557.SGD"],"gpt_icon":1},{"id":"1184639598","title":"药捷安康-B上市首日盘中涨幅扩大至80%，中签一手赚超5000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1184639598","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1184639598?lang=zh_cn&edition=full","pubTime":"2025-06-23 10:53","pubTimestamp":1750647238,"startTime":"0","endTime":"0","summary":"6月23日，$药捷安康-B(02617)$上市首日盘中涨幅扩大至80%，中签一手赚超5000港元，总市值超94亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d1fe578ee46cbe0d24c33435ff25ae5"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"gpt_icon":0},{"id":"1135221454","title":"异动解读 | 药捷安康-B上市首日大涨63%，创新药研发引爆投资热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1135221454","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1135221454?lang=zh_cn&edition=full","pubTime":"2025-06-23 09:34","pubTimestamp":1750642469,"startTime":"0","endTime":"0","summary":"6月23日，生物制药公司药捷安康-B在港交所主板挂牌上市，股价表现亮眼。开盘即大涨63.12%，报21.45港元，展现出投资者对这家创新药企的强烈兴趣。药捷安康是一家专注于肿瘤、炎症及心脏代谢疾病小分子创新疗法的生物制药公司。此次IPO，药捷安康发行1528.1万股H股，每股发售价13.15港元，募集资金净额约1.61亿港元。药捷安康的成功上市不仅反映了投资者对生物医药行业的持续看好，也凸显了市场对具有创新能力和强大研发实力的企业的青睐。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"gpt_icon":1},{"id":"1192489379","title":"异动解读 | 药捷安康-B上市首日大涨63%，IPO超额认购3420倍","url":"https://stock-news.laohu8.com/highlight/detail?id=1192489379","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192489379?lang=zh_cn&edition=full","pubTime":"2025-06-23 09:34","pubTimestamp":1750642447,"startTime":"0","endTime":"0","summary":"6月23日，生物制药公司药捷安康-B在港交所主板挂牌上市，股价表现强劲。盘中，该股大涨63.12%，引发市场广泛关注。药捷安康-B此次IPO反应热烈。公司公开发售部分获得约3420倍超额认购，显示投资者对其前景充满信心。作为一家专注于小分子创新药物开发的公司，药捷安康主要致力于肿瘤、炎症及心脏代谢疾病领域的治疗。投资者看好公司在生物制药领域的创新能力和市场潜力，推动其股价在上市首日大幅上涨。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02617"],"gpt_icon":0},{"id":"1133456971","title":"新股首日｜药捷安康-B飙涨超64%，佰泽医疗涨超24%，三花智控破发开跌7%","url":"https://stock-news.laohu8.com/highlight/detail?id=1133456971","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1133456971?lang=zh_cn&edition=full","pubTime":"2025-06-23 09:23","pubTimestamp":1750641828,"startTime":"0","endTime":"0","summary":"6月23日，港股三只新股正式挂牌港交所，药捷安康-B飙涨超64%，公开发售获逾3400倍认购；佰泽医疗涨超24%，公开发售获近26倍认购；三花智控跌超7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/5d8fb95e65f042f352c6313989391357"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2328871848.SGD","LU2580892789.USD","BK0076","BK0197","LU2298064838.USD","002050","BK0187","LU2238339852.HKD","LU2580892862.HKD","SGXZ49509284.SGD","LU1969619763.USD","BK0188","BK0070","02617","02609","LU1328615791.USD","159891","02050","BK0028","LU1023057109.AUD","LU0359202008.SGD","LU1064130708.USD","LU0359201612.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.1163},{"period":"1month","weight":1.2814},{"period":"ytd","weight":1.2814}],"compareEarnings":[{"period":"1week","weight":0.0093},{"period":"1month","weight":-0.0093},{"period":"3month","weight":0.1542},{"period":"6month","weight":0.2662},{"period":"1year","weight":0.3537},{"period":"ytd","weight":0.2034}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的 MTK 抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括 TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和 BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和 Pan-FGFR 实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}